Late Tenecteplase Not Beneficial for Stroke Patients With LVOs
PHOENIX — Selected stroke patients did not benefit clinically from having the window of tenecteplase therapy extended beyond the first few hours of stroke onset, the randomized TIMELESS trial found. In patients with large-vessel occlusions (LVOs) and evidence of salvageable tissue on perfusion imaging — most who also received endovascular thrombectomy — functional outcomes at […]
Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer
A novel drug combination led to clinically meaningful antitumor activity in metastatic ESR1-mutated, estrogen receptor-positive (ER+)/HER2-negative breast cancer that had progressed on CDK4/6 inhibition, a small prospective study showed. Adding the selective estrogen receptor modulator (SERM) lasofoxifene to abemaciclib (Verzenio) resulted in a median progression-free survival (PFS) of 56 weeks, and a 24-week clinical benefit […]
Emicizumab Can Delay Immunosuppressive Tx in Acquired Hemophilia A
Early emicizumab (Hemlibra) prophylaxis alone prevented clinically relevant bleeds in patients with newly diagnosed acquired hemophilia A, while avoiding the infectious complications of immunosuppressive therapy in this vulnerable population, a phase II study showed. Over 12 weeks of therapy, a high-dose regimen of the factor VIIIa mimetic antibody yielded a low mean breakthrough bleeding rate […]
Generic Fluticasone–Salmeterol Inhaler for COPD Matches Branded Product
A generic fluticasone-salmeterol (Wixela Inhub) maintenance inhaler was clinically equivalent to name-brand Advair Diskus for chronic obstructive pulmonary disease (COPD), a propensity score-matched cohort study found. With approximately 3 months of routine use, the generic form of the inhaled corticosteroid and long-acting beta-agonist (ICS-LABA) inhaler was shown to carry a similar incidence of first moderate-to-severe […]
ICI/TKI Combo Maintains Survival Benefit in Advanced RCC
SAN FRANCISCO — First-line nivolumab (Opdivo) plus cabozantinib (Cabometyx) continued to demonstrate clinically meaningful survival benefits in advanced renal cell carcinoma (RCC). An update of the CheckMate 9ER trial, which compared the immune checkpoint inhibitor/tyrosine kinase inhibitor (TKI) doublet with the TKI sunitinib (Sutent), showed that after 44 months of median follow-up, median progression-free survival […]
JAK Inhibitor Improves Symptoms, Anemia in Myelofibrosis
Myelofibrosis treatment with the Janus kinase (JAK) inhibitor momelotinib resulted in clinically significant improvements in symptoms and spleen response compared with danazol for symptomatic, JAK inhibitor-exposed patients with anemia and intermediate- or high-risk disease, the phase III MOMENTUM trial showed. A significantly greater proportion of patients in the momelotinib group reported a ≥50% reduction in […]
Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx
A 79-year-old man with a 12-year history of clinically localized prostate cancer presented to a hospital with a urethral stricture. He had developed radiation cystitis and low-grade non-invasive urothelial carcinoma of the bladder some time after he received proton therapy following his prostate cancer diagnosis. In the process of prepping the patient for cystoscopic dilation […]
Can Prostate Cancer Patients on AS Delay Surgery at Progression?
Among men with clinically localized prostate cancer who continued active surveillance (AS) after biopsy progression, delaying surgery did not significantly reduce recurrence-free survival (RFS) rates or increase the risk of adverse pathology, researchers reported. In a prospectively followed cohort, men on AS who underwent early radical prostatectomy (RP) had a 3-year RFS rate of 80%, […]
PSMA PET Plus MRI Better Detects Clinically Significant Prostate Cancers
MRI combined with prostate-specific membrane antigen (PSMA) PET improved the detection of clinically significant prostate cancer compared with MRI alone, and can potentially allow for a reduction in the number of biopsies needed for diagnosis, according to results from the PRIMARY trial. The combined approach demonstrated an increase in negative predictive value for detecting prostate […]